Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis
Abstract Background Recently, the addition of inhaled corticosteroid (ICS) to long-acting muscarinic antagonist (LAMA) and long-acting beta-agonist (LABA) combination therapy has been recommended for patients with COPD who have severe symptoms and a history of exacerbations because it reduces the ex...
Main Authors: | Akira Koarai, Mitsuhiro Yamada, Tomohiro Ichikawa, Naoya Fujino, Tomotaka Kawayama, Hisatoshi Sugiura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-021-01777-x |
Similar Items
-
Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
by: Akira Koarai, et al.
Published: (2020-04-01) -
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
by: Singh D, et al.
Published: (2019-02-01) -
Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
by: Tariq SM, et al.
Published: (2017-06-01) -
Clinical implications of blood eosinophil count in patients with non-asthma–COPD overlap syndrome COPD
by: Song JH, et al.
Published: (2017-08-01) -
The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study
by: Wang CY, et al.
Published: (2016-11-01)